Advertisement
Home Tags Cystic Fibrosis

Tag: Cystic Fibrosis

1999 to 2020 Saw Decrease in Cystic Fibrosis-Related Mortality

Simultaneously, median age at time of death increased over time

Drinking Water Quality Tied to Lung Infections in Patients With Cystic Fibrosis

High levels of sulfate, vanadium, molybdenum in water supplies may increase the risk for nontuberculous mycobacteria pulmonary infections

Delays in Cystic Fibrosis Care Tied to Persistent Impairment in Growth

Infants with age at first event of ≥33 days remained at significantly reduced height through 1, 3, and 5 years

Challenged Urine Bicarbonate Excretion Tied to CFTR Function in Cystic Fibrosis

Higher urine bicarbonate excretion linked to better lung function, pancreatic sufficiency, lower relative risk for chronic pseudomonas infections

Newborn Screening for Cystic Fibrosis Less Accurate in Minorities

Detection of at least one CFTR variant higher in non-Hispanic White people with CF, lowest for Blacks, Asians, Hispanics

Racial, Ethnic-Minority Infants Older at First Cystic Fibrosis Evaluation

Median weight for age z-score at 1 to 2 years lower for infants categorized as Black, AI/AN, Hispanic, other versus non-Hispanic White

Higher BMI Linked to Improved Lung Function in Cystic Fibrosis

Patients with normal weight have increased odds for CF-related diabetes and exocrine pancreatic insufficiency versus overweight patients

Intravenous antibiotics do not achieve greater sustained eradication of Pseudomonas aeruginosa in patients with cystic fibrosis compared with oral therapy

IV, Oral Antibiotics Comparable for Treating P. aeruginosa in CF

Results do not support use of IV antibiotics to eradicate P. aeruginosa in cystic fibrosis, authors say
A heterogeneous pattern on ultrasound examination of the liver may help identify children with cystic fibrosis at increased risk for developing advanced cystic fibrosis liver disease

Ultrasound May ID Children at Risk for Cystic Fibrosis Liver Disease

A heterogeneous liver pattern could indicate a higher risk for advanced cystic fibrosis liver disease
For patients with cystic fibrosis with Phe508del-minimal function genotypes

Elexacaftor-Tezacaftor-Ivacaftor Efficacious for Cystic Fibrosis

Percentage of FEV1 higher at four weeks and through 24 weeks with treatment versus placebo